Related Experiment Video
Updated: Aug 5, 2026
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
Characterising the Economic Burden of Functional Dyspepsia: A Cost-of-Illness Study of Direct and Indirect Costs
Daan H C A Bosch1,2, Brigitte A B Essers3, Abraham B Beckers1,2
1Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Background:
Functional dyspepsia (FD) is a prevalent disorder of gut-brain interaction (DGBI) and is associated with substantial impact on health care utilisation. However, analyses examining patient-specific characteristics that contribute to this burden remain limited. This study assessed the economic burden of patients with FD and examined patient-specific characteristics related to costs.
Methods:
Patients who had been recruited for a randomised controlled trial completed several questionnaires. Health care utilisation and productivity losses were measured using the iMTA Medical Consumption Questionnaire and Productivity Cost Questionnaire. Participants also completed the EuroQol 5-Dimension 5-Level, Nepean Dyspepsia Index, Generalised Anxiety Disorder-7, and Patient Health Questionnaire-9. Non-parametric bootstrapping was applied to calculate the mean annual costs. Multivariable linear regression was used to identify patient-specific characteristics associated with costs.
Results:
Data were obtained from 73 participants (median age 39 years; 75% female). Mean annual total costs accounted for €12,192 (2.5th to 97.5th percentiles, €1125 to €36,369), of which €10,240 (2.5th to 97.5th percentiles, €0 to €34,771) were indirect costs. Higher disease-specific quality of life (QoL) was associated with lower annual total costs (regression slope = -€4726 per 0.1-point increase in QoL; 95% CI, -€7636 to -€1815; p = 0.002), while symptom severity, generic health-related QoL or scores for anxiety or depression were not significantly associated.
Conclusion:
Patients with poorer disease-specific QoL, but not necessarily those with more severe symptoms or higher scores for anxiety and depression, are particularly likely to incur higher annual costs. Understanding the nature of costs and associated patient characteristics is essential for enabling more targeted strategies.
Trial Registration:
The TENDER trial was registered on Clinicaltrials.gov under NCT03652571 on August 17, 2018.
Related Concept Videos
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications
01:17Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems related to...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...